Rekvina Laboratories Ltd

Rekvina Laboratories Limited has submitted the Recommendations of the Committee of Independent Directors (IDC) regarding the open offer made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The open offer is to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital, at ₹10 per share, totaling ₹2,89,01,000. The IDC has deemed the offer price fair and reasonable, advising public shareholders to independently evaluate and make informed decisions. The recommendations were published in newspapers on June 25, 2026.

Rekvina Laboratories Ltd announced that its Committee of Independent Directors (IDC) met on June 24, 2026, to provide recommendations on an open offer. The offer, made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel, aims to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital, at ₹10 per share. The total consideration is ₹2,89,01,000. The IDC has deemed the offer price fair and reasonable in accordance with SEBI SAST Regulations, though public shareholders are advised to make their own informed decisions. The committee reviewed various documents including the Public Announcement, Detailed Public Statement, and valuation reports.

Rekvina Laboratories Ltd has received a Letter of Offer from Vivro Financial Services Private Limited concerning an open offer to the public shareholders. The offer is being made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital, at a price of ₹10 per share. This open offer is in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The offer is not conditional on a minimum acceptance level.

Vivro Financial Services Pvt Ltd, acting as the Manager to the Open Offer, has submitted a Letter of Offer to BSE for the equity shareholders of Rekvina Laboratories Ltd. The open offer is being made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel (collectively, the 'Acquirers') to acquire up to 28,90,100 equity shares, representing 26% of the expanded share capital. The offer price is ₹10 per equity share, payable in cash. This open offer is in compliance with SEBI (SAST) Regulations and is not conditional upon any minimum acceptance level. Certain shares under lock-in are not permitted to be tendered.

Rekvina Laboratories Ltd has announced the approval of its standalone audited financial results for the quarter and year ended March 31, 2026, along with the statement of assets, liabilities, and cash flow statement for the same period. The board of directors approved these results in a meeting held on May 21, 2026, which commenced at 6:30 PM and concluded at 7:55 PM. The company operates in a single reportable business segment in India and the board did not recommend any dividend for the financial year ended March 31, 2026.

Rekvina Laboratories Ltd has announced its standalone audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results along with the statement of Assets & Liabilities, Cash Flow statement, and an unmodified Audit Report in their meeting held on May 21, 2026. The meeting commenced at 6:30 PM and concluded at 7:55 PM. The company operates in a single reportable business segment in India and the board has not recommended any dividend for the financial year ended March 31, 2026.

Rekvina Laboratories Ltd has announced a Board of Directors meeting scheduled for May 21, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026, under Indian Accounting Standards (Ind AS). The company has also announced the closure of the Trading Window for designated persons from April 01, 2026, until 48 hours after the financial results are made public, in accordance with the Company’s Code of Conduct for Prevention of Insider Trading.

Rekvina Laboratories Ltd has received an Open Offer from Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel to acquire up to 28,90,100 fully paid-up equity shares, representing 26% of the Expanded Share Capital. The offer is priced at ₹ 10/- per Equity Share, payable in cash. The offer is not conditional upon any minimum level of acceptance and does not require any statutory approvals except for those mentioned in the Draft Letter of Offer. The Acquirers have the option to revise the Offer Price prior to the commencement of the last 1 (One) Working Day before the commencement of the Tendering Period.

Rekvina Laboratories Ltd has received a draft Letter of Offer from Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel for an open offer to acquire up to 28,90,100 fully paid-up equity shares, representing 26% of the expanded share capital. The offer price is ₹ 10/- (Rupees Ten Only) per Equity Share, payable in cash. The open offer is in compliance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended. The offer is not conditional upon any minimum level of acceptance and is not a competing offer.

Rekvina Laboratories Ltd. has received a Detailed Public Statement from Vivro Financial Services Private Limited regarding an Open Offer to the Public Shareholders of the company. The Open Offer is made by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel as per the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation 2011. The statement was published in financial newspapers such as Financial Express (English and Gujarati) and Jansatta (Hindi) on March 24, 2026.